Bugworks

Linked-in

LG – Lead Generation
LO – Lead Optimization
P1 – Phase 1
P2 – Phase 2

BWC0977

IV + Oral step down small molecule agent for treating critical care infections

LG

LO

P1

P2

GYROX-2

Oral small molecule agent for treating community infections

LG

LO

P1

P2

Coverage:

  • Critical priority pathogens including carbapenem resistant Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
  • High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae
  • Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei

DARE-1

Small molecule oral immuno-oncologic agents for treating multiple cancers

LG

LO

P1

P2

Coverage:

  • Adenosine pathway Implied in CRC, NSCLC, TNBC, PANCREAS, PROSTATE, RCC, HNSCC
  • No FDA approved small molecule drug yet
  • Available immuno-oncology drugs are biologics presenting with huge cost and toxicity liabilities
  • Has a potential for combination with approved immune checkpoint drugs, cytotoxics and targeted therapies

TMET

(Tumour Micro Environment Targets)

LG

LO

P1

P2

Coverage:

  • Hypoxia Modulators
  • Next-generation checkpoint inhibitors
  • Novel kinase inhibitors

Partners

Partner-CTA
to top